CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons
Objective: A promising and potential direction to treat PD is to develop new non-dopaminergic drugs without producing dyskinesia, as well as arresting and even reversing…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content
Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity
Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype
Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease
Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III
Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay
Objective: To know the consumption habits of Yerba Mate in a population of Parkinson's disease (PD) patients from Uruguay. To compare the consumption habits of…STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort
Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »